NDAINJECTIONINJECTABLE
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DOCETAXEL (docetaxel) by Teva is 12. Approved for breast cancer, non-small cell lung cancer, urothelial cancer and 1 more indications. First approved in 2013.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a microtubule-stabilizing chemotherapy agent approved for breast cancer, non-small cell lung cancer, urothelial cancer, and bladder cancer. It works by binding to free tubulin and promoting microtubule assembly while inhibiting disassembly, leading to mitotic inhibition and cell death. This generic injectable is a mature, widely-used taxane in oncology.
Peak
Generic docetaxel faces moderate competitive pressure (30% intensity) as a mature peak-stage product with limited growth upside; career stability depends on managed care and oncology portfolio depth.
Mechanism of Action
12.1 Mechanism of Action Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously…
Worked on DOCETAXEL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.